IBRX Latest Headlines

ImmunityBio Secures $100 Million in Financing—$75 Million Non-Dilutive Boost Sharpens Global Expansion and Pipeline Advancement

Market Chameleon (Tue, 31-Mar 7:51 AM)

ImmunityBio Bolsters Balance Sheet With New Financing Moves

at www.tipranks.com (Tue, 31-Mar 11:17 AM)

ImmunityBio secures $75M financing under Oberland deal

at seekingalpha.com (Tue, 31-Mar 9:28 AM)

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky

at www.tipranks.com (Tue, 31-Mar 12:15 AM)

ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva

at www.tipranks.com (Mon, 30-Mar 2:14 PM)

ImmunityBio's Pivotal NMIBC Trial Achieves Key Milestone: No Additional Enrollment Needed for ANKTIVA Plus BCG Study

Market Chameleon (Thu, 26-Mar 7:50 AM)

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

at www.benzinga.com (Thu, 26-Mar 10:04 AM)

ImmunityBio Gains First Asian Regulatory Approval for ANKTIVA—What Does This Mean for Global Expansion?

Market Chameleon (Mon, 23-Mar 7:32 AM)

NCCN Guidelines Expand ANKTIVA Plus BCG Use for Papillary-Only Bladder Cancer – What This Means for ImmunityBio and Patients

Market Chameleon (Tue, 17-Mar 7:51 AM)

ImmunityBio’s Breakthrough: Large-Scale NK Cell Manufacturing Opens Door to ‘World Bank’ of Cancer Therapies

Market Chameleon (Fri, 13-Mar 7:50 AM)

ImmunityBio’s ANKTIVA Earns FDA Resubmission for Papillary NMIBC: Long-Term Data Highlights Durable Outcomes

Market Chameleon (Mon, 9-Mar 7:33 AM)

ImmunityBio’s Trial: ANKTIVA Plus BCG Shows Promising Results in Bladder Cancer Study

Market Chameleon (Thu, 26-Feb 7:44 AM)

ImmunityBio’s Leadership Highlighted as Dr. Patrick Soon-Shiong Joins Renowned Cancer Experts at Milken Institute Summit

Market Chameleon (Tue, 24-Feb 11:17 AM)

ImmunityBio's ANKTIVA Gains Saudi FDA Green Light, Securing Key MENA Partnerships for Bladder and Lung Cancer Launch

Market Chameleon (Mon, 23-Feb 11:07 AM)

IBRX’s ANKTIVA Achieves 700% Revenue Growth, First Global Lung Cancer Approval, and Rapid Expansion Across 33 Countries

Market Chameleon (Mon, 23-Feb 8:12 AM)